Related Experiment Videos
Pilot study of d-penicillamine, vitamins and minerals in multiple sclerosis
Abstract:
A pilot study of the effect of D-penicillamine in multiple sclerosis (MS) was undertaken because of D-penicillamine's activity against RNA neurotropic viruses, because it is effective against the auto-immune disease, rheumatoid arthritis, and because both viruses and autoimmunity have been implicated in multiple sclerosis. We have treated 16 patients with advanced MS, nine on full doses (2-2.25 grams/day) and seven whose treatment was permanently stopped for reasons other than adverse reactions. There has been some improvement in most of those whose treatment was not withdrawn, and no change or deterioration in those not continued on the therapeutic regimen. Despite use of a high dosage regimen, such as has evoked intolerable side effects in a high percentage of patients with rheumatoid arthritis, we have experienced few side effects in a total of 48 patients suffering from diseases with auto-immune components, a finding we speculate is due to replacement of nutrients inactivated or removed by D-penicillamine, and to supplementation with selected nutrients.
Insights
D-penicillamine showed potential benefits for multiple sclerosis (MS) patients in a pilot study. Most patients continuing treatment experienced improvement, with few side effects observed.
Area of Science:
- Neurology
- Immunology
- Virology
Background:
- Multiple sclerosis (MS) is implicated with viral and autoimmune components.
- D-penicillamine exhibits antiviral and anti-autoimmune properties, showing efficacy in rheumatoid arthritis.
- These properties suggest D-penicillamine as a potential therapeutic agent for MS.
Purpose of the Study:
- To investigate the effects of D-penicillamine in patients with advanced multiple sclerosis.
- To assess the safety and efficacy of D-penicillamine treatment in MS.
Main Methods:
- A pilot study involving 16 patients with advanced MS.
- Treatment involved D-penicillamine at high doses (2-2.25 grams/day).
- Patients were monitored for efficacy and adverse reactions.
Main Results:
- Nine patients received full doses; seven discontinued treatment for non-adverse reaction reasons.
- Most patients continuing treatment showed some improvement.
- Patients not continuing treatment showed no change or deterioration.
- Few side effects were observed, even at high doses, across 48 patients with autoimmune conditions.
Conclusions:
- D-penicillamine may offer therapeutic benefits for multiple sclerosis patients.
- The drug appears well-tolerated in autoimmune disease patients, even at high doses.
- Nutrient replacement and supplementation may mitigate side effects.